MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Summary

This phase II trial is studies how well Akt inhibitor MK2206 works in treating patients with stage I-III breast cancer that can be removed by surgery. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2011-04

Primary completion

2013-07

Completion

2013-07

Drugs

Indications